Overview

An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial

Status:
Terminated

Trial end date:
2007-10-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of Study 20060172 was to measure echocardiographic parameters and biomarkers in a subgroup of study subjects enrolled in Study 20050222 (the RED-HF Trial). This substudy 20060172 was terminated early due to feasibility constraints. All subjects enrolled in 20060172 were also enrolled in Study 20050222, which is ongoing. Study data will be analyzed when Study 20050222 ends, since unblinding before then would adversely affect Study 20050222.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Amgen

Treatments:

Darbepoetin alfa

Criteria

Inclusion Criteria:

- Signed informed consent for Study 20060172

- Randomized into Study 20050222

Exclusion Criteria:

- Any condition or situation that, in the investigator's opinion, may put the subject at
significant risk, render the subject unsuitable for accurate echocardiography, may
confound the study results, or may interfere significantly with the subject's
participation in Study 20060172 or in Study 20050222.